Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity, inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.
Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, The Netherlands.
I M
IM
Keularts
S
S
Béguin
C
C
de Zwaan
H C
HC
Hemker
D000789:Angina, Unstable / Q000097:blood* / Q000188:drug therapy; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D006493:Heparin; D013917:Thrombin; D000077466:Tirofiban